Fenwal has received the US Food and Drug Administration (FDA) approval for its Aurora plasmapheresis system.
Plasmapheresis is an automated process in which plasma is taken from donated blood and the remaining components like red cells and platelets are returned to the donor.
The plasma collection system is built on the proprietary separation technology that powers the company’s Autopheresis-C system.
Fenwal chief technology officer William Cork said Aurora features new capabilities such as an interactive touch-screen display with intuitive menus and icons, and comes with the Fenwal DXT Relay software, which delivers productivity reports and enables remote procedure set-up and paperless documentation.
The DXT Relay software provides plasma center professionals with easy-to-read, on-demand reports that aggregate donor and procedure data from multiple Aurora systems at different locations.
The reports track specific performance indicators and can be used to identify opportunities for improvement and training.